New RSV pill shows promise in early human trial
NCT ID NCT06170242
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental oral drug called EDP-323 in 142 healthy adults who were deliberately infected with RSV. The goal was to see if the drug is safe and can reduce the amount of virus in the nose compared to a placebo. Results will help determine if EDP-323 could be a future treatment for RSV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
hVIVO Services Limited
London, United Kingdom